Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIBA: Ribavirin exposure optimization using abbreviated AUC-guided dosing
2010-020371-22Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribavirin in chronic hepatitis C (CHC), sponsored by Radboud University Medical Center. Primary endpoint: Proportion of patients with target AUC0-4h after second dose. Started Oct 2010; status: completed.
02
Drugs
ribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2010-020371-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020371-22.